Neoadjuvant Therapy in Melanoma Tied to High Pathological Response Rates
Researchers concluded that the ability to achieve pCR correlated to improved recurrence-free survival in melanoma.
All articles by Agata Boxe
No Link Found Between HRD and Pathologic Response in Triple-Negative Breast Cancer
One of the study’s primary objectives was to detect an association between homologous repair deficiency and pathologic response.
Paclitaxel Plus Olaparib Linked to Better Outcomes in Some Breast Cancer Patients
Paclitaxel plus olaparib may result in a higher pathological complete response (pCR) rate than paclitaxel plus carboplatin — followed by epirubicin and cyclophosphamide — but only in some groups of patients.
Extended Letrozole Provides Benefit After Adjuvant Tamoxifen
Extended adjuvant treatment with additional 5 years of letrozole was associated with a 19% reduction in invasive disease-free survival events, said authors.
Heparin Derivative CX-01 May Boost Standard AML Induction
The new findings suggest that CX-01 may strengthen the efficacy of standard AML induction.
Novel Metric Sheds Light on When Adverse Events May Occur
Longitudinal toxicity analysis can be used to guide adverse event interventions.
Sequential Exposure to FOLFOXIRI Plus Bevacizumab Shows Benefit in Unresectable mCRC
The reintroduction of FOLFOXIRI/bev in the progressive setting may provide a further benefit in mCRC.
Depth of Response to TKIs, Immunotherapies Correlates to Longer PFS and OS
Researchers from the FDA analyzed 10 RCTs conducted in patients with unresectable or metastatic melanoma who were treated with 1 of 3 drug types.
Ipilimumab, BRAF/MEK Inhibitors Are Active in Patients With Resected Melanoma Who Recurred on Adjuvant Anti–PD-1
For patients who recur on anti–PD-1, they should be considered resistant to anti–PD-1 and must change to a different type of medication, said Dr Owen.
Study Found Gilteritinib Superior to Salvage Chemotherapy in FLT3-Mutated Refractory AML
The researchers examined 37 recurrently mutated genes in AML using next-generation sequencing.
-
Loading...
-
Loading...
Next post in ASCO 2019
